- Avant Technologies (OTCQB: AVAI) and Ainnova Tech are exploring a new venture to integrate dementia detection into their AI-based platform.
- The companies are considering acquiring or licensing a patented technology for early dementia detection using a 5-minute blood test.
- The Vision AI platform currently assesses risks for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease through advanced AI algorithms.
Avant Technologies, Inc. (OTCQB: AVAI) and joint venture partner Ainnova Tech, Inc. announced their intention to integrate early dementia detection into Ainnova's Vision AI platform. This initiative aligns with the companies' mission to expand AI-powered early detection and preventative health solutions globally. The proposed technology uses AI algorithms and hardware to detect dementia via a 5-minute blood test.
The Vision AI platform already utilizes four integrated algorithms to screen for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. This screening is performed using an automated, low-cost retinal imaging device that analyzes retinal images, blood pressure, and lab test data to deliver comprehensive risk assessments.
The exploration of this patented technology reflects Avant and Ainnova's commitment to enhancing their preventative screening platform's capabilities in disease detection. While the technology's integration into the Vision AI platform is still in the exploratory stage, the companies aim to license or acquire it to further advance their positions in healthcare technology.
Vinicio Vargas, CEO of Ainnova, commented on the potential impact of this technology, emphasizing its accessibility, speed, and scalability for early intervention and targeted treatment strategies, aspiring to reach millions of patients worldwide.
